Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Corbeil Essonnes – page 12

3 332 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Corbeil Essonnes at a glance
3 332
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 332 trials in Corbeil Essonnes

Open in trial search

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Neoplasm malignant

Recruiting

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Huntington's disease

Recruiting

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

Type 1 diabetes mellitus

Recruiting

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Type 1 diabetes mellitus

Recruiting

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Guillain-Barre syndrome

Recruiting

A Study of ANX005 for Patients Recently Diagnosed with Guillain-Barré Syndrome to Evaluate How the Drug Works in the Body and Its Safety

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Humanised IgG4 monoclonal antibody against C1Q
  • Sponsor:Annexon Inc.

Non-small cell lung cancer

Recruiting

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Recruiting

A study of MK-1084 and pembrolizumab for patients with resected KRAS G12C-mutant non-small cell lung cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm

Recruiting

Study of ATX-898 alone and in drug combination for patients with advanced solid tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Antares Therapeutics Inc.

Small cell lung cancer metastatic+1

Recruiting

Study of ZL-1310, BI 764532 and atezolizumab in patients with advanced small cell lung cancer and neuroendocrine tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Neoplasm

Recruiting

Phase 2 Study Evaluating Safety and Efficacy of Belzutifan in Adults with Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Sjogren's syndrome

Recruiting

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

  • Glycemic Control Studies
  • Cardiovascular Risk Management
  • Weight Management Therapies
02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

  • Novel Drug Combinations
  • Maintenance Therapy Optimization
  • Minimal Residual Disease Studies
03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

  • Immunotherapy Development
  • Alternative Treatment Strategies
  • Disease Management Protocols
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.